title: Outcome of acute myeloid leukemia and high-risk myelodysplastic syndrome according to health insurance status.
abstract: BACKGROUND
  Age, cytogenetic status, and molecular features are the most important prognostic factors in acute myeloid leukemia (AML). This study aimed to analyze the outcomes of patients with AML or high-risk myelodysplastic syndrome (MDS) according to insurance status.
  
  
  METHODS
  A retrospective chart review was performed, covering all patients with AML and high-risk MDS evaluated and treated at Akron General Medical Center between 2002 and 2012. A Cox regression model was analyzed to account for survival over time, adjusted for insurance type, while controlling for patient age at diagnosis and patient risk of mortality.
  
  
  RESULTS
  A total of 130 adult patients (age ≥ 18 years) were identified. Insurance information was available for 97 patients enrolled in the study; 3 were excluded because of self-pay status. Cox regression analysis with insurance type as the predictor found that overall survival declines over time and that the rate of decline may be influenced by insurance type (χ(2)(2) = 6.4; P = .044). The likelihood of survival in patients with Medicaid or Medicare without supplemental insurance was .552 (95% CI, .338-.903; P = .018) times the likelihood in patients who had Medicare with supplemental insurance. To explain the difference, variables of age, gender, and risk of mortality were added to the model. Age and risk of mortality were found to be significant predictors of survival. The addition of insurance type to the model did not significantly contribute (χ(2)(3) = 3.83; P = .147).
  
  
  CONCLUSIONS
  No significant difference in overall survival was observed when patients with AML or high-risk MDS were analyzed according to their health insurance status. The overall survival was low in this study compared with the national average. Early referral to a specialized center or possible clinical trial enrollment may be a good alternative to improve outcome.
authors.affiliation: Internal Medicine, Akron General Medical Center, Akron, OH.
authors.forename: Ali
authors.initials: A
authors.lastname: Al-Ameri
authors.affiliation: Internal Medicine, Akron General Medical Center, Akron, OH. Electronic address: ankitanand55@gmail.com.
authors.forename: Ankit
authors.initials: A
authors.lastname: Anand
authors.affiliation: Internal Medicine, Akron General Medical Center, Akron, OH.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdelfatah
authors.affiliation: Internal Medicine, Akron General Medical Center, Akron, OH.
authors.forename: Zeyad
authors.initials: Z
authors.lastname: Kanaan
authors.affiliation: Internal Medicine, Akron General Medical Center, Akron, OH.
authors.forename: Tracy
authors.initials: T
authors.lastname: Hammonds
authors.affiliation: Internal Medicine, Akron General Medical Center, Akron, OH.
authors.forename: Nairmeen
authors.initials: N
authors.lastname: Haller
authors.affiliation: University of Oklahoma Health Sciences Center, Oklahoma City, OK.
authors.forename: Mohamad
authors.initials: M
authors.lastname: Cherry
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007348:Insurance, Health; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000453:epidemiology* / Q000401:mortality; D063868:Patient Outcome Assessment; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
keywords: AML/MDS; Cytogenetic data; Insurance; Outcome; Survival